{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T09:28:48Z","timestamp":1768728528586,"version":"3.49.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the dissolution effect of alteplase (rt-PA) on arterial blood clots of patients with hypertensive cerebral hemorrhage <jats:italic>in vitro<\/jats:italic> and analyze the optimal concentration and action time of rt-PA for intracranial hematomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The arterial blood of 35 patients with confirmed hypertensive cerebral hemorrhage were collected, centrifuged, and the serum was aspirated to prepare the blood clot model. The 0.125, 0.25, 0.5, 1, 2, and 3 mg t-PA, 20,000 U, and 40,000 U urokinase (u-PA) were taken for the corresponding blood clot for dissolution test. The blood clot volume and dissolution volume was measured at 0, 30, 60, 90, 120, and 150 min.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Without intervention, the blood clot volume of men was higher than that of women at 0, 30, 60, and 90 min (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). Without intervention, hematocrit (HCT) was correlated with blood clot volume and the correlation decreased with time. The 30, 60, and 90 min dissolution curves of each group showed an upward trend (<jats:italic>P<\/jats:italic> &amp;lt; 0.05), and the dissolution curves tended to be flat at 120 min and 150 min. The dissolution volume of.125 mg\/3 ml, 0.25 mg\/3 ml, 0.5 mg\/3 ml rt-PA, 20,000 U, 40,000 U u-PA was higher than that of 1, 2, 3 mg\/ml rt-PA (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). The dissolution volume of.125 mg\/3 ml, 0.25 mg\/3 ml, 0.5 mg\/3 ml rt-PA was not significantly different from 20,000 and 40,000 U u-PA (<jats:italic>P<\/jats:italic> &amp;gt; 0.05). Gender differences did not affect the effects of the above drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:italic>In vitro<\/jats:italic>, low-concentration rt-PA has a better dissolution effect, and it shows a time-dependent effect, reaching the highest effect in 90 min.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.729727","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T04:51:25Z","timestamp":1645159885000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Dissolution Effect of Alteplase on Arterial Blood Clot Model of Hypertensive Intracerebral Hemorrhage Patients in vitro"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoming","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaogang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"She","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1161\/CIR.0b013e31823ac046","article-title":"Heart disease and stroke statistics-2012 update: a report from the American Heart Association","volume":"125","author":"Roger","year":"2012","journal-title":"Circulation."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"46","author":"Hemphill","year":"2015","journal-title":"Stroke."},{"key":"B3","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1586\/14737175.2015.1059755","article-title":"Minimally invasive treatment of intracerebral hemorrhage","volume":"15","author":"Rennert","year":"2015","journal-title":"Expert Rev Neurother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(13)60986-1","article-title":"Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial","volume":"382","author":"Mendelow","year":"2013","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(19)30195-3","article-title":"Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial","volume":"393","author":"Hanley","year":"2019","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S0002-9343(00)00380-6","article-title":"Third-generation thrombolytic drugs","volume":"109","author":"Verstraete","year":"2000","journal-title":"Am J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/83358","article-title":"The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling","volume":"7","author":"Nicole","year":"2001","journal-title":"Nat Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3171\/jns.2002.97.4.0954","article-title":"Fibrinolysis therapy achieved with tissue plasminogen activator and aspiration of the liquefied clot after experimental intracerebral hemorrhage: rapid reduction in hematoma volume but intensification of delayed edema formation","volume":"97","author":"Rohde","year":"2002","journal-title":"J Neurosurg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12975-012-0188-3","article-title":"Tissue plasminogen activator induced delayed edema in experimental porcine intracranial hemorrhage: reduction with plasminogen activator inhibitor-1 administration","volume":"3","author":"Keric","year":"2012","journal-title":"Transl Stroke Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/cdd.2012.86","article-title":"Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity","volume":"19","author":"Parcq","year":"2012","journal-title":"Cell Death Differ."},{"key":"B11","doi-asserted-by":"publisher","first-page":"E2410","DOI":"10.1073\/pnas.1305010110","article-title":"Tissue plasminogen activator regulates Purkinje neuron development and survival","volume":"110","author":"Li","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3389\/fncel.2015.00415","article-title":"Impacts of tissue-type plasminogen activator (tPA) on neuronal survival","volume":"9","author":"Chevilley","year":"2015","journal-title":"Front Cell Neurosci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/RLI.0b013e31823cc75c","article-title":"In vitro and in vivo high-intensity focused ultrasound thrombolysis","volume":"47","author":"Wright","year":"2012","journal-title":"Invest Radiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.RVI.0000106384.63463.A5","article-title":"When urokinase was gone: commentary on another year of thrombolysis without urokinase","volume":"15","author":"Gates","year":"2004","journal-title":"J Vasc Interv Radiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-3-211-09469-3_30","article-title":"Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial","volume":"105","author":"Morgan","year":"2008","journal-title":"Acta Neurochir Suppl."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5853\/jos.2016.00864","article-title":"Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: an update","volume":"19","author":"An","year":"2017","journal-title":"J Stroke."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.729727\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T04:51:27Z","timestamp":1645159887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.729727\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":16,"alternative-id":["10.3389\/fneur.2022.729727"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.729727","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]},"article-number":"729727"}}